整联蛋白α2表达与甲状腺微小乳头状癌复发风险的相关性研究  

The expression of integrinα2 is associated with the risk of recurrence in papillary thyroid microcarcinoma

作　　者：程枫 周斌[1] 毛卫波[2] 朱忆凌[2] CHENG Feng;ZHOU Bin;MAO Weibo;ZHU Yiling(Department of Head and Neck Surgery,the Fifth Affiliated Hospital of Wenzhou Medical University/Lishui Municipal Central Hospital,Lishui,Zhejiang 323000,China;Department of Pathology,the Fifth Affiliated Hospital of Wenzhou Medical University/Lishui Municipal Central Hospital,Lishui,Zhejiang 323000,China)

机构地区：[1]温州医科大学附属第五医院/丽水市中心医院头颈(甲状腺)外科,浙江丽水323000 [2]温州医科大学附属第五医院/丽水市中心医院病理科,浙江丽水323000

出　　处：《重庆医学》2025年第4期874-878,883,共6页Chongqing Medical Journal

基　　金：浙江省医药卫生科技计划项目(2022KY1425)。

摘　　要：目的探讨甲状腺微小乳头状癌(PTMC)组织中整联蛋白α2(ITGA2)表达与复发风险的相关性。方法收集2022年12月至2023年6月于该院经手术病理确诊的98例PTMC患者的肿瘤组织和癌旁组织标本,采取免疫组织化学方法观察ITGA2在PTMC患者的肿瘤组织和癌旁组织中的表达情况。收集所有患者的临床病理特征,比较ITGA2阳性组和阴性组患者间的临床特征差异性。根据肿瘤复发风险分层标准,比较ITGA2表达在组间的差异性。结果PTMC肿瘤组织中ITGA2的表达水平高于癌旁组织,差异有统计学意义(P<0.001)。多因素logistic回归分析结果显示,BRAF基因突变(OR=2.668)、较大的肿瘤合并直径(TTD,OR=1.111)是ITGA2高表达的危险因素(P<0.05)。ITGA2阳性表达与肿瘤复发风险相关(P=0.009)。结论ITGA2可以作为一个新的分子标志物应用于临床。Objective To investigate the correlation between the expression of integrinα2(ITGA2)and recurrence risk of papillary thyroid microcarcinoma(PTMC).Methods PTMC and para-carcinoma tissue were collected from patients who underwent surgery and pathologically confirmed at the hospital from December 2022 to June 2023,and the expression of ITGA2 in PTMC and paracarcinoma tissue were observed using immunohistochemistry method.Clinical characteristics of all patients were collected and the differences in clinicopathological characteristics between patients in ITGA2-positive and-negative groups were compared.According to the risk stratification criteria for tumor recurrence,the differences in ITGA2 expression between groups were compared.Results The expression level of ITGA2 in PTMC was higher than that in para-carcinoma tissues,and the difference was statistically significant(P<0.001).Multivariate logistic regression analysis showed that BRAF mutation(OR=2.668)and larger total tumor diameter(TTD,OR=1.111)were risk factors for ITGA2 overexpression(P<0.05).ITGA2 positive expression was associated with the risk of tumor recurrence(P=0.009).Conclusion ITGA2 can be used as a novel molecular biomarker for clinical application.

关 键 词：甲状腺微小乳头状癌 临床病理特征 整联蛋白α2 免疫组织化学 复发危险分层 

分 类 号：R736.1[医药卫生—肿瘤]